AU
UK
CA
NZ
IND
US
Last update at 2026-06-23T19:08:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Rakovina Therapeutics Highlights Strong H1 Progress and Unveils Strategic Priorities for H2 2025
Mon 30 Jun 25, 07:00 AM3 Asian Penny Stocks With Market Caps Below US$8B
Wed 19 Mar 25, 04:04 AMFebruary 2025 Penny Stocks Worth Watching
Tue 18 Feb 25, 02:11 AMCSPC Pharmaceutical Group And 2 Other Penny Stocks To Watch This Year
Mon 20 Jan 25, 03:08 AMCSPC Pharmaceutical Group And 2 Other Promising Penny Stocks To Watch
Fri 20 Dec 24, 04:11 PMAstraZeneca Inks Agreement to Boost Cardiovascular Pipeline
Tue 08 Oct 24, 05:05 PMAstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline
Mon 07 Oct 24, 12:04 PM| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 5205.62M | 5936.16M | 7389.37M | 7582.26M | 6847.10M |
| Minority interest | - | -10.79000M | -187.92700M | -140.66000M | -82.93900M |
| Net income | 4203.05M | 4605.33M | 5873.32M | 6091.39M | 5605.19M |
| Selling general administrative | - | 1148.77M | 1308.77M | 1172.84M | 1009.82M |
| Selling and marketing expenses | - | 9217.30M | 10055.95M | 10337.42M | 10443.42M |
| Gross profit | 18468.78M | 21599.26M | 24397.35M | 22256.41M | 21135.09M |
| Reconciled depreciation | - | 1339.45M | 1117.49M | 1047.94M | 865.47M |
| Ebit | 4299.29M | 5709.96M | 7415.27M | 7559.09M | 6817.40M |
| Ebitda | 5825.26M | 6864.51M | 8532.76M | 8607.03M | 7682.87M |
| Depreciation and amortization | 1525.97M | 1154.55M | 1117.49M | 1047.94M | 865.47M |
| Non operating income net other | - | - | - | - | - |
| Operating income | 4299.29M | 5709.96M | 7680.12M | 7559.09M | 6817.40M |
| Other operating expenses | 23856.68M | 25157.93M | 26919.25M | 24177.27M | 21071.92M |
| Interest expense | 41.79M | 43.67M | 25.90M | 24.89M | 7.66M |
| Tax provision | - | 1239.90M | 1288.83M | 1350.21M | 1158.97M |
| Interest income | - | - | - | - | - |
| Net interest income | - | -43.67300M | -26.76800M | -24.89100M | -7.66400M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1008.76M | 1319.34M | 1316.68M | 1350.21M | 1158.97M |
| Total revenue | 28155.97M | 30867.89M | 34599.37M | 30936.90M | 27866.87M |
| Total operating expenses | 14169.49M | 15889.30M | 16717.23M | 15496.78M | 14340.14M |
| Cost of revenue | 9687.19M | 9268.63M | 10202.02M | 8680.49M | 6731.78M |
| Total other income expense net | 906.32M | 226.20M | -290.75100M | 23.17M | 29.70M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | - | 4338.82M | 6306.12M | 6232.05M | 5688.12M |
| Net income applicable to common shares | - | - | - | - | 5605.19M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 52007.66M | 44388.99M | 46282.17M | 41769.77M | 34741.58M |
| Intangible assets | 3090.39M | 2609.51M | 2198.55M | 1908.11M | 467.85M |
| Earning assets | - | - | - | - | - |
| Other current assets | 830.75M | 569.43M | -321.37400M | - | 177.75M |
| Total liab | 13529.05M | 10522.70M | 12392.10M | 10127.90M | 7913.35M |
| Total stockholder equity | 36950.66M | 32264.69M | 33203.21M | 30197.53M | 25986.67M |
| Deferred long term liab | - | - | - | 35.81M | 41.98M |
| Other current liab | 6770.85M | 6235.60M | 6323.22M | 6652.38M | 5565.00M |
| Common stock | 12319.16M | 11032.75M | 10899.41M | 10899.41M | 10899.41M |
| Capital stock | - | 11032.75M | 10899.41M | 10899.41M | 10899.41M |
| Retained earnings | - | 23344.08M | 24034.86M | 21135.90M | 19187.67M |
| Other liab | - | - | - | - | 631.68M |
| Good will | 261.61M | 234.90M | 234.90M | 234.90M | 149.98M |
| Other assets | - | - | -1973.36385M | 1008.15M | 1342.49M |
| Cash | 6781.97M | 6777.20M | 12015.22M | 10298.01M | 9283.64M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11335.13M | 9634.03M | 10182.57M | 8958.00M | 7226.04M |
| Current deferred revenue | 737.55M | - | -8.31042M | - | - |
| Net debt | -6067.96760M | -6269.86900M | -11308.32200M | -9715.46300M | -9189.59800M |
| Short term debt | 512.77M | 451.19M | 599.84M | 295.56M | 38.42M |
| Short long term debt | - | 392.20M | 450.22M | 153.48M | 0.00000M |
| Short long term debt total | 714.01M | 507.33M | 706.90M | 582.54M | 94.04M |
| Other stockholder equity | 24631.50M | -2112.13700M | -1731.06400M | -1837.77500M | 15087.26M |
| Property plant equipment | - | - | - | - | 9563.92M |
| Total current assets | 24780.60M | 21888.14M | 26744.94M | 23957.16M | 20336.50M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | - | 28090.33M | 25410.82M |
| Short term investments | 3091.55M | 1473.11M | 1077.05M | 3574.86M | 1443.41M |
| Net receivables | 10634.17M | 9938.39M | 10835.38M | 3937.97M | 6548.65M |
| Long term debt | - | - | 0.00000M | 28.95M | - |
| Inventory | 3442.17M | 3130.01M | 3138.66M | 2554.86M | 2480.37M |
| Accounts payable | 3313.97M | 2613.00M | 2841.74M | 2010.07M | 1622.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | -1410.66100M | - | - |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 619.76M | 1529.24M | 819.64M | 8868.33M | 4601.85M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 27227.06M | 22500.85M | 19537.22M | 17812.61M | 14405.07M |
| Capital lease obligations | - | 115.13M | 256.69M | 400.11M | 94.04M |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
| Investments | -3858.20000M | 607.27M | -6795.98400M | 630.71M | -450.05600M |
| Change to liabilities | - | - | 487.07M | 232.57M | 629.28M |
| Total cashflows from investing activities | -3858.20000M | 607.27M | -6795.98400M | -637.32600M | -2129.51300M |
| Net borrowings | 19.05M | -27.84000M | -135.23900M | -222.16700M | 76.68M |
| Total cash from financing activities | -5253.33200M | -2300.98100M | -1904.07300M | -2196.60600M | -1470.97600M |
| Change to operating activities | - | - | 920.34M | -59.87200M | 894.92M |
| Net income | 4605.33M | 7389.37M | 7582.26M | 6847.10M | 6391.02M |
| Change in cash | -4573.46900M | 2489.99M | -1058.85700M | 1800.25M | 3141.22M |
| Begin period cash flow | 11541.35M | 8000.85M | 9059.71M | 7259.46M | 4118.24M |
| End period cash flow | 6296.50M | 10490.84M | 8000.85M | 9059.71M | 7259.46M |
| Total cash from operating activities | 4534.66M | 4178.81M | 7627.06M | 4636.63M | 6739.61M |
| Issuance of capital stock | -510.06100M | -258.59600M | - | - | 0.00000M |
| Depreciation | 1339.45M | 1117.49M | 1047.94M | 865.47M | 808.81M |
| Other cashflows from investing activities | -123.96000M | 365.65M | 308.74M | 269.00M | -10.01400M |
| Dividends paid | 3441.01M | 2999.25M | 2096.96M | 1690.76M | 1527.69M |
| Change to inventory | 9.20M | -528.62400M | -42.75000M | -617.06700M | 601.44M |
| Change to account receivables | 736.60M | -3294.53400M | -566.54800M | -943.55200M | -445.45200M |
| Sale purchase of stock | -2336.26131M | -200.35800M | -14.21100M | -263.51200M | 0.00000M |
| Other cashflows from financing activities | 504.89M | 926.46M | 702.81M | -143.33100M | 56.72M |
| Change to netincome | - | - | -310.38500M | -446.11100M | -909.02900M |
| Capital expenditures | 2678.88M | 1893.07M | 2722.69M | 1758.45M | 1576.61M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | -205.91572M | -2745.53900M | 798.12M | -1387.91800M | 1680.18M |
| Stock based compensation | 210.45M | 258.63M | 160.73M | 17.73M | 9.13M |
| Other non cash items | -1414.65828M | -1841.14100M | -1961.98200M | -1705.75400M | -2149.52300M |
| Free cash flow | 1855.79M | 2285.75M | 4904.37M | 2878.18M | 5163.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CSPCY CSPC Pharmaceutical Group Limited |
-0.12 3.45% | 3.36 | 22.00 | 8.50 | 0.49 | 2.70 | 3.13 | 16.79 |
| LLY Eli Lilly and Company |
5.00 0.45% | 1107.08 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
7.79 3.37% | 239.08 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
4.75 2.07% | 234.76 | 86.32 | 14.33 | 5.89 | 50.46 | 7.04 | 24.44 |
| AZN AstraZeneca PLC |
4.59 2.60% | 181.02 | 30.69 | 19.23 | 5.30 | 6.45 | 5.72 | 17.23 |
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, the company provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food products; and healthcare services. It has a strategic collaboration with AstraZeneca PLC to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple therapies for obesity and type 2 diabetes. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.
No.896 Zhongshandong Street, Shijiazhuang, China, 050035
| Name | Title | Year Born |
|---|---|---|
| Mr. Dongchen Cai | Exec. Chairman | 1954 |
| Mr. Cuilong Zhang | Vice-Chairman & CEO | 1969 |
| Mr. Chunlei Li | Exec. Director & Chief Scientist | 1976 |
| Mr. Kin Man Chak | Exec. Director | 1966 |
| Mr. Weidong Pan | Exec. Director | 1970 |
| Mr. Huaiyu Wang | Exec. Director | 1963 |
| Mr. Zhenguo Wang | Exec. Director | 1970 |
| Dr. Qingxi Wang | Exec. Director | 1966 |
| Dr. Hao Jiang | Exec. Director | 1983 |
| Mr. Jinxu Wang | Sr. VP | 1971 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...